Type 2 Diabetes and Cardiovascular Risk Management

Definition and Pathophysiology

Type 2 diabetes mellitus (T2DM) is a major cardiovascular risk condition. It is associated with a two- to four-fold increase in lifetime cardiovascular disease (CVD) risk and approximately doubles cardiovascular risk on average. Its cardiovascular manifestations include atherosclerotic cardiovascular disease (ASCVD), coronary artery disease (CAD), myocardial infarction, stroke, heart failure (HF), atrial fibrillation (AF), aortic disease, and peripheral artery disease (PAD). Diabetes also substantially increases the risk of chronic kidney disease (CKD), which itself promotes cardiovascular disease and amplifies cardiovascular and all-cause mortality.

The excess risk is mediated by the combined effects of hyperglycaemia, hypertension, dyslipidaemia, obesity, smoking and other conventional risk factors, together with diabetes-specific vascular and metabolic abnormalities. Diabetes is associated with inflammation, thrombosis and accelerated atherosclerosis. In CKD, additional mechanisms include vascular stiffness and accelerated medial calcification related to disturbed calcium–phosphate metabolism. Patients with advanced CKD are particularly vulnerable to structural cardiac abnormalities, HF and sudden cardiac death.

The relationship between glycaemia and cardiovascular disease is complex. Glycaemic control is important for prevention of microvascular complications, but intensive glucose lowering alone has shown little or no consistent effect on cardiovascular complications in T2DM. Cardiovascular benefit depends substantially on comprehensive risk-factor management and, in appropriate patients, selection of glucose-lowering therapies with demonstrated cardiovascular effects.

Diabetes may also contribute to arrhythmogenesis through diabetic neuropathy and adverse metabolic effects, independently of coexisting CAD, previous myocardial infarction or HF. Nevertheless, the risk of arrhythmia and sudden cardiac death is most often determined by the presence and severity of underlying cardiovascular disease. Conduction disease and the need for pacemaker therapy may be more frequent in T2DM, although management follows the same principles as in patients without diabetes.

Clinical Presentation and Symptoms

T2DM may be clinically silent while vascular disease progresses. Many patients presenting with CVD have previously undiagnosed diabetes; systematic screening for diabetes is therefore recommended in patients with CVD.

The clinical consequences of diabetes may present through any major cardiovascular phenotype:

• CAD, including chronic coronary syndromes and acute coronary syndromes

• HF across the spectrum of left ventricular ejection fraction

• AF and other arrhythmias

• Ischaemic stroke

• PAD

• CKD with associated cardiovascular complications

Symptoms are determined by the cardiovascular manifestation rather than by diabetes alone. The source material does not provide a detailed symptom profile or symptom-based diagnostic algorithm for each condition. Diabetes-related AF may be accompanied by a greater symptom burden and AF burden, although improved metabolic and risk-factor management has been associated with reduced AF symptoms and better maintenance of sinus rhythm in cohort studies.

Obesity, reduced exercise capacity, hypertension and dyslipidaemia commonly coexist and should be considered part of the clinical cardiovascular phenotype. Weight reduction and increased physical activity can improve metabolic control and exercise capacity, even when cardiovascular event reduction is not demonstrated in every intervention study.

Cardiovascular Risk Assessment

Screening for cardiovascular and kidney disease

All patients with diabetes should be assessed for:

• ASCVD

• Severe target-organ damage (TOD)

• HF

• AF

• CKD

• Other clinically relevant cardiovascular disease, including PAD

Conversely, patients with CVD should be screened systematically for diabetes because undiagnosed T2DM is common and has major therapeutic and prognostic implications.

Diabetes combined with CVD, particularly when diabetes develops at a younger age, is associated with a particularly adverse prognosis. The presence of CKD further increases risk and should influence both risk classification and treatment selection.

Risk categories

Most adults with T2DM, particularly from middle age onwards, are at high or very high cardiovascular risk. Patients with severe TOD may be considered to have very high risk, comparable to those with established CVD. Most other patients with T2DM are regarded as being at high ASCVD risk.

A possible exception is the patient with:

• Short-duration diabetes, such as less than 10 years

• Good disease control

• No evidence of TOD

• No additional ASCVD risk factors

Such patients may be considered to have moderate cardiovascular risk.

Risk is heterogeneous, and risk-factor treatment should be considered in all patients with diabetes, at least from 40 years of age. Assessment should incorporate comorbidities, lifetime risk, frailty, expected treatment benefit and patient preferences.

SCORE2-Diabetes

In patients with T2DM who have neither symptomatic ASCVD nor severe TOD, 10-year cardiovascular risk should be estimated using SCORE2-Diabetes. The score estimates the risk of fatal and non-fatal cardiovascular events, including myocardial infarction and stroke, and assists classification into low, moderate, high or very high risk.

Other diabetes-specific tools include the ADVANCE risk score and the UKPDS risk engine. Their use requires caution because they are based on older cohort data.

Evaluation and Physical Examination

The assessment should be comprehensive and directed toward identifying established cardiovascular disease, severe TOD and modifiable risk factors. It should include evaluation of:

• Smoking status

• Body weight and obesity

• Physical activity and exercise capacity

• Blood pressure

• Lipid abnormalities

• Glycaemic control

• Clinical evidence of CAD, HF, AF or PAD

• Kidney disease and its severity

• Diabetes duration and complications

• Frailty and treatment preferences

Physical examination findings are not detailed in the source material. The clinical examination should therefore be understood as part of a broader assessment for cardiovascular and renal disease rather than as a diabetes-specific examination protocol.

Diagnostics

Electrocardiography and rhythm assessment

The source material does not provide a detailed ECG strategy for cardiovascular risk assessment in T2DM. Diabetes is associated with increased risk of AF, ventricular arrhythmias, sudden cardiac death and conduction disturbances. AF risk is influenced by hypertension, CAD, prior myocardial infarction, HF, stroke, glucose control and diabetic neuropathy.

Cardiac imaging and functional assessment

The source material does not specify a universal imaging protocol for asymptomatic patients with diabetes. Imaging and functional testing should be guided by the suspected cardiovascular manifestation, clinical risk and symptoms.

HF assessment is particularly important because diabetes increases HF risk, and SGLT2 inhibitors reduce HF hospitalization across the spectrum of ejection fraction. The source material refers to a diagnostic algorithm for HF but does not reproduce its specific diagnostic steps.

Coronary and peripheral vascular assessment

Patients with diabetes and established CAD require comprehensive secondary prevention. Decisions regarding invasive evaluation and revascularization should be based on the clinical presentation and coronary anatomy. In multivessel disease, diabetes is an important factor in revascularization strategy selection, but the source material does not provide a procedural algorithm or numerical thresholds.

Evaluation for PAD is also recommended as part of cardiovascular assessment, although the specific diagnostic tests and thresholds are not described in the source material.

Biomarkers and Laboratory Findings

Glycated haemoglobin

HbA1c is central to assessment of glycaemic control and is incorporated into some diabetes-specific cardiovascular risk models. Glycaemic targets should be individualized. A near-normal HbA1c, below 6.5% or 53 mmol/mol, is described as optimal for minimizing microvascular complications, whereas a less stringent target of ≤8% may be appropriate for older patients and those with established cardiovascular disease.

Intensive HbA1c lowering alone should not be expected to reduce cardiovascular events in T2DM.

Lipid measurements

Lipid assessment is essential because dyslipidaemia is a major modifiable cardiovascular risk factor. The principal lipid parameter used for treatment is LDL cholesterol (LDL-C). Non-HDL cholesterol and apolipoprotein B are also relevant measures for cardiovascular care, although specific treatment thresholds are not supplied in the source material.

The therapeutic objective in diabetes and CKD is to achieve the largest safe absolute reduction in LDL-C. CKD may attenuate the relative benefit obtained per unit LDL-C reduction, making intensive lipid lowering particularly relevant in patients at high absolute risk.

Renal assessment

Evaluation of kidney disease should include estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). These measures determine CKD severity, cardiovascular risk and eligibility for therapies such as SGLT2 inhibitors and finerenone.

The source material identifies the following criteria for finerenone use in T2DM with CKD:

• eGFR >60 mL/min/1.73 m2 with UACR ≥34 mg/mmol (≥300 mg/g), or

• eGFR 25–60 mL/min/1.73 m2 with UACR ≥3 mg/mmol (≥30 mg/g)

Potassium must be monitored because mineralocorticoid receptor antagonists can cause hyperkalaemia. The pivotal finerenone trials excluded patients with potassium >4.8 mmol/L.

Treatment and Management

Lifestyle and Risk-Factor Management

Lifestyle intervention is the foundation of cardiovascular prevention and should be individualized through patient-centred communication.

Smoking cessation

Smoking cessation is a primary treatment target in patients with diabetes and CVD. Smoking should be addressed routinely and actively, rather than treated as a secondary consideration.

Physical activity

Exercise should be introduced in all patients with CVD and T2DM according to the principle that every step counts. Increased daily physical activity, supplemented where appropriate by structured exercise sessions, improves exercise capacity and metabolic control.

In patients with obesity and T2DM, increasing physical activity should be combined with weight reduction. Exercise interventions may improve exercise capacity even when changes in conventional cardiovascular risk factors are not significant.

Weight management

Weight reduction is a key component of treatment in obesity and T2DM. A structured lifestyle programme involving nutritional counselling, meal replacement and exercise produced substantial weight loss and improved HbA1c and blood pressure in the cited trial population, although these effects diminished over time among participants with poor adherence.

Weight loss of at least 10% at one year was associated with lower subsequent mortality in long-term follow-up. Reductions in body fat were associated with lower risk of both HF with reduced ejection fraction and HF with preserved ejection fraction, while reductions in waist circumference were associated with lower risk of HF with preserved ejection fraction.

Some intensive weight-management programmes can produce remission to a non-diabetic state with discontinuation of glucose-lowering drugs in a substantial proportion of patients at one year.

Diet

A Mediterranean dietary pattern supplemented with olive oil and/or nuts reduces the incidence of major cardiovascular events in patients with CVD. Nutritional management should be incorporated into the overall risk-factor strategy rather than considered separately from weight, activity, blood pressure and lipid treatment.

Blood pressure

Hypertension is common in diabetes and approximately doubles medium- to long-term risk of major cardiovascular events compared with patients without diabetes. Blood-pressure control is therefore a central component of prevention.

The source material does not specify a universal blood-pressure target or individual drug doses. Treatment should be integrated with management of lipid abnormalities, obesity, glycaemia and kidney disease.

Glucose-Lowering Therapy

General principles

In patients with T2DM and ASCVD, severe TOD or high cardiovascular risk, an SGLT2 inhibitor or GLP-1 receptor agonist is recommended as first-line monotherapy, according to the cited European and American recommendations. This represents a shift from the former approach of using metformin universally as initial therapy.

In patients with established CAD, SGLT2 inhibitors and/or GLP-1 receptor agonists are recommended to reduce cardiovascular events, in addition to lifestyle and standard treatment of blood pressure and lipids.

Therapy should be selected according to:

• Established ASCVD or CAD

• HF

• CKD

• Cardiovascular risk category

• Obesity and the need for weight loss

• Kidney function

• Tolerability and adverse effects

• Patient preferences and treatment burden

SGLT2 inhibitors

SGLT2 inhibitors reduce glucose through glucosuria and have concurrent diuretic and natriuretic effects. Their cardiovascular effects include substantial reduction in HF hospitalization and improved renal outcomes. The benefits on HF hospitalization or cardiovascular death appear to be preserved across levels of eGFR in the trial populations described.

In patients with T2DM and CKD, SGLT2 inhibitors should be initiated alongside an ACE inhibitor or angiotensin receptor blocker after the first clinical evidence of CKD. They may be initiated down to at least an eGFR of 20 mL/min/1.73 m2 and continued until kidney replacement therapy is required, although their glucose-lowering effect is markedly reduced at low eGFR.

SGLT2 inhibitors also reduce AF incidence. Pooled data cited in the source material found an 18% reduction in AF incidence in diabetes trials and reductions of up to 37% in HF populations with or without diabetes.

In patients with T1DM and CKD, the balance between potential cardiovascular and renal benefit and the high absolute risk of ketoacidosis remains uncertain.

The source material does not provide dose regimens for individual SGLT2 inhibitors.

GLP-1 receptor agonists

GLP-1 receptor agonists reduce major cardiovascular events in selected populations with T2DM and elevated cardiovascular risk. Liraglutide and semaglutide have demonstrated cardiovascular benefit in the cited outcome studies, and semaglutide has also shown renal and cardiovascular protection in patients with diabetes and CKD.

GLP-1 receptor agonists are particularly relevant when weight reduction is a major treatment objective. Gastrointestinal adverse effects are more frequent than with SGLT2 inhibitors and may contribute to the greater weight loss associated with this class.

The source material does not provide doses for liraglutide, semaglutide or other GLP-1 receptor agonists.

Other glucose-lowering therapies

The cardiovascular effects of glucose-lowering drugs are heterogeneous.

• Metformin has observational associations with lower AF incidence, but its overall cardiovascular effect is not established in the source material as a basis for universal first-line therapy.

• Sulfonylureas have been consistently associated with increased AF risk in the cited evidence.

• Insulin may promote adipogenesis and cardiac fibrosis and has not been presented as a cardiovascular risk-reducing strategy.

• Dipeptidyl peptidase-4 inhibitors and several other glucose-lowering therapies have been evaluated in cardiovascular outcome studies, but the source material does not establish a uniform cardiovascular benefit for the class.

• Pioglitazone has evidence of benefit after ischaemic stroke or transient ischaemic attack in selected patients with insulin resistance, but its role in general cardiovascular risk management in T2DM is not defined here.

• Intensive glucose lowering should not be used with the expectation of reducing cardiovascular events independently of comprehensive risk-factor treatment.

Lipid Management

Statin-based therapy reduces major atherosclerotic events in patients with CKD, diabetes and established cardiovascular risk. It does not meaningfully slow CKD progression.

Intensive LDL-C lowering with statins, alone or combined with ezetimibe, has been shown to be safe in the cited CKD populations. In patients with stage G3 CKD, the LDL-C-lowering effect of evolocumab was preserved and cardiovascular benefit appeared unmodified by baseline eGFR.

When LDL-C remains inadequately controlled despite statin therapy, additional agents with outcome data include:

• Ezetimibe

• PCSK9 inhibitors, including evolocumab and alirocumab

• Inclisiran

• Bempedoic acid in statin-intolerant patients

The source material does not provide drug doses or specific LDL-C numerical targets. It emphasizes achieving the greatest safe absolute LDL-C reduction according to cardiovascular risk.

Renin–Angiotensin System Inhibition and Finerenone

ACE inhibitors and angiotensin receptor blockers

Renin–angiotensin system (RAS) blockade with an ACE inhibitor or an angiotensin receptor blocker reduces progression to kidney failure in patients with diabetes and overt nephropathy. ARBs also slow progression from microalbuminuria to overt nephropathy.

RAS inhibition is recommended when CKD is clinically diagnosed. Combining an ACE inhibitor with an ARB is not recommended because it increases hyperkalaemia and acute kidney injury without providing additional demonstrable benefit for kidney failure or cardiovascular outcomes.

SGLT2 inhibitor combination

Combining an SGLT2 inhibitor with an ACE inhibitor or ARB reduces kidney failure risk and HF hospitalization in patients with T2DM and CKD. Available subgroup analyses suggest that combining an SGLT2 inhibitor with a mineralocorticoid receptor antagonist does not materially alter the main safety findings, although evidence remains limited.

Finerenone

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces kidney outcomes and the composite cardiovascular outcome of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or HF hospitalization in patients with T2DM and CKD already receiving maximal ACE inhibitor or ARB therapy.

It is recommended in addition to RAS inhibition for patients meeting the eGFR and albuminuria criteria described above. Potassium monitoring is mandatory because of hyperkalaemia risk.

The source material does not provide finerenone dosing or a detailed potassium-based titration schedule.

Antiplatelet and Antithrombotic Treatment

Patients with diabetes have altered platelet activation and increased atherothrombotic risk. However, aspirin for primary prevention requires careful consideration because the balance between cardiovascular benefit and bleeding risk is uncertain. The source material does not provide a universal recommendation for aspirin primary prevention or a dose.

In patients with established CAD, acute coronary syndrome or coronary intervention, antiplatelet treatment should follow the relevant acute and chronic coronary syndrome recommendations. Ticagrelor has been studied in patients with diabetes and stable CAD who had a history of previous percutaneous coronary intervention, but treatment selection and duration depend on the coronary presentation, revascularization strategy and bleeding risk.

The source material does not provide antiplatelet doses or complete duration regimens.

Management of Established Coronary Disease

Management of diabetes with established CAD should begin with:

• A healthy dietary pattern

• Weight management

• Physical activity

• Smoking cessation

• Blood-pressure control

• Intensive lipid management

• Appropriate glucose-lowering therapy

SGLT2 inhibitors and/or GLP-1 receptor agonists are recommended in T2DM with CAD to reduce cardiovascular events. Standard CAD therapies, including antiplatelet, antihypertensive and lipid-lowering treatment where indicated, remain necessary; newer glucose-lowering therapies are additional rather than substitutive treatments.

In stable coronary disease, an initial conservative or invasive strategy should be individualized. In patients with diabetes and multivessel CAD, the choice between coronary artery bypass grafting and percutaneous coronary intervention requires consideration of the extent and complexity of coronary disease and the overall clinical setting. The source material does not provide specific anatomic thresholds or procedural dosing recommendations.

Management of Heart Failure

Diabetes increases the risk of HF, and CKD further heightens this risk. SGLT2 inhibitors are recommended in patients with diabetes and chronic HF irrespective of left ventricular ejection fraction to reduce HF hospitalization.

The source material does not provide a complete HF drug regimen, doses or a detailed acute decompensation pathway. It does, however, support the use of SGLT2 inhibitors as a cardiovascular and HF-directed therapy independent of their glucose-lowering effect.

Management of Atrial Fibrillation and Arrhythmias

Diabetes-related cardiovascular risk management may reduce AF symptoms and AF burden and may facilitate maintenance of sinus rhythm. However, robust evidence is limited, and different glucose-lowering therapies have variable associations with AF.

Important considerations include:

• Intensive HbA1c lowering to <6.0% or <42 mmol/mol did not prevent incident AF.

• Sulfonylureas have been consistently associated with increased AF risk.

• Metformin has been associated observationally with lower incident AF.

• SGLT2 inhibitors may reduce incident AF in people with diabetes and HF and in people with HF without diabetes.

• Comprehensive treatment of obesity, hypertension, dyslipidaemia and other comorbidities is essential.

Diabetes may increase the risk of conduction disturbances and pacemaker requirement, but the general management of these problems should not differ from that in patients without diabetes.

The source material does not describe anticoagulation criteria, antiarrhythmic drug doses or ablation strategies.

Guideline Recommendations

The principal recommendations supported by the source material are summarized below.

Risk-factor intensification should be individualized through shared decision-making, taking account of 10-year and lifetime risk, comorbidities, frailty, anticipated benefit and patient preferences.

Prognosis and Follow-up

Diabetes worsens outcomes across CAD, stroke, HF, AF and PAD. The coexistence of diabetes with cardiovascular or renal disease substantially increases cardiovascular and all-cause mortality. Risk is particularly high in patients with severe TOD, CKD, established ASCVD or early-onset diabetes.

Follow-up should be continuous and multifactorial. It should reassess:

• Cardiovascular symptoms and new manifestations of ASCVD

• HF symptoms and clinical status

• AF and other arrhythmias where clinically indicated

• Blood pressure

• Weight, physical activity and smoking status

• HbA1c and overall glycaemic management

• Lipid levels and response to treatment

• eGFR and UACR

• Serum potassium when using finerenone or other therapies associated with hyperkalaemia

• Treatment adherence, tolerability and patient priorities

Long-term benefit depends on sustained implementation. Lifestyle effects may diminish when adherence declines, whereas pharmacological strategies should be reviewed and titrated sequentially according to cardiovascular, renal and metabolic risk.

An interdisciplinary approach is recommended. Coordination among cardiology, diabetology, primary care, nephrology and other relevant disciplines supports shared decision-making and individualized treatment, with the dual goals of improving prognosis and preserving health-related quality of life.